FINWIRES · TerminalLIVE
FINWIRES

三華智能制御の第1四半期の利益は2.7%増加

By

-- 浙江三華智能制御(SHE:002050、HKG:2050)は、2026年第1四半期の帰属利益が前年同期の9億340万元から2.7%増の9億2760万元となったと、水曜日に香港証券取引所に提出した書類で明らかにした。 同社の香港上場株は木曜午後の取引で4%上昇し、中国上場株は5%近く上昇した。 1株当たり利益は前年同期の0.24元から0.22元に減少した。 売上高は前年同期の76億7000万元から1.4%増の77億7000万元となった。

Related Articles

Research

Research Alert: Xpo Q1 Earnings Beat As Margins Expand And Tonnage Turns Positive

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:XPO reported Q1 EPS of $1.01 vs. $0.73 a year ago, beating consensus by $0.13, while revenue of $2.1B grew 7% and beat estimates by $60M. Adjusted EBITDA surged 15% to $319M, demonstrating accelerating momentum across the business. We believe the combination of margin expansion, positive volume inflection, and strong cash generation supports XPO's trajectory toward accelerating free cash flow generation. North American LTL performance was solid, with adjusted operating ratio improving 200 bps to 83.9% and 20% growth in adjusted operating income. Critically, tonnage per day turned positive at +0.1% vs. Q4 2025's -4.5% decline, marking an inflection point and suggesting early demand stabilization signs. Yield growth excluding fuel remained robust at 4.0%, supported by service improvements and AI-driven network optimization, while cash from operations grew 29% to $183M. In our view, XPO's insourcing strategy and operational leverage position the company well for continued margin expansion and cash flow growth.

$XPO
Research

Research Alert: Cigna: Mcr Improvement Supports Q1 Eps Beat, Guidance Raise

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CI reported Q1 2026 adjusted EPS of $7.79 (+16% Y/Y), beating the $7.61 consensus and prompting a $0.10 raise to annual EPS guidance. Total revenues rose 5% Y/Y to $68.5B, due to Evernorth Health Services' growth of 9% Y/Y to $58.4B, while Cigna Healthcare's revenues fell 21% Y/Y reflecting the Medicare business divestiture. The strong Evernorth performance, including 11% Y/Y growth in Pharmacy Benefit Services due to favorable drug mix and 6% Y/Y growth in Specialty and Care Services, supports the company's strategic pivot toward higher-margin services. Management maintained Medical Care Ratio guidance at 83.7%-84.7% for 2026, demonstrating continued cost discipline amid operational improvements. Operational efficiency improved with its SG&A expense ratio declining 100bps to 5.4%, while Cigna Healthcare pre-tax margins expanded 430bps to 13.2% and the Medical Care Ratio improved to 79.8% from 82.2%, primarily benefiting from the Medicare divestiture.

$CI
Research

JPMorgan Downgrades Kaiser Aluminum to Underweight From Neutral, Adjusts Price Target to $142 From $124

$KALU